Lamivudine therapy for hepatitis B in renal transplantation
Antiviral therapies are associated with an increased risk of acute rejection in transplant patients. The aim of the present study was to evaluate the efficacy and safety of lamivudine therapy for hepatitis B virus (HBV) infection in renal transplant patients. Six patients were included in this study. They received 150 mg/day of lamivudine during a follow-up period of 24 months. The laboratory tests monitored were HBV DNA, HBsAg, HBeAg, ALT, gamma-GT, serum creatinine and blood cyclosporine levels. The HBV DNA became undetectable in four patients as early as in the third month of treatment. After six months, the viral load was also negative in the other two patients, and remained so until 18 months of follow-up. The medication was well tolerated with no major side effects. Lamivudine was safe and effective in blocking HBV replication in renal transplant patients without any apparent increase in the risk of graft failure for the 24-month period of study.
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2002
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000200008 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0100-879X2002000200008 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0100-879X20020002000082002-02-08Lamivudine therapy for hepatitis B in renal transplantationSantos,F.R.L.Haiashi,A.R.Araújo,M.R.T.Abensur,H.Romão Junior,J.E.Noronha,I.L. Lamivudine Kidney transplantation Hepatitis B Antiviral therapies are associated with an increased risk of acute rejection in transplant patients. The aim of the present study was to evaluate the efficacy and safety of lamivudine therapy for hepatitis B virus (HBV) infection in renal transplant patients. Six patients were included in this study. They received 150 mg/day of lamivudine during a follow-up period of 24 months. The laboratory tests monitored were HBV DNA, HBsAg, HBeAg, ALT, gamma-GT, serum creatinine and blood cyclosporine levels. The HBV DNA became undetectable in four patients as early as in the third month of treatment. After six months, the viral load was also negative in the other two patients, and remained so until 18 months of follow-up. The medication was well tolerated with no major side effects. Lamivudine was safe and effective in blocking HBV replication in renal transplant patients without any apparent increase in the risk of graft failure for the 24-month period of study.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.35 n.2 20022002-02-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000200008en10.1590/S0100-879X2002000200008 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Santos,F.R.L. Haiashi,A.R. Araújo,M.R.T. Abensur,H. Romão Junior,J.E. Noronha,I.L. |
spellingShingle |
Santos,F.R.L. Haiashi,A.R. Araújo,M.R.T. Abensur,H. Romão Junior,J.E. Noronha,I.L. Lamivudine therapy for hepatitis B in renal transplantation |
author_facet |
Santos,F.R.L. Haiashi,A.R. Araújo,M.R.T. Abensur,H. Romão Junior,J.E. Noronha,I.L. |
author_sort |
Santos,F.R.L. |
title |
Lamivudine therapy for hepatitis B in renal transplantation |
title_short |
Lamivudine therapy for hepatitis B in renal transplantation |
title_full |
Lamivudine therapy for hepatitis B in renal transplantation |
title_fullStr |
Lamivudine therapy for hepatitis B in renal transplantation |
title_full_unstemmed |
Lamivudine therapy for hepatitis B in renal transplantation |
title_sort |
lamivudine therapy for hepatitis b in renal transplantation |
description |
Antiviral therapies are associated with an increased risk of acute rejection in transplant patients. The aim of the present study was to evaluate the efficacy and safety of lamivudine therapy for hepatitis B virus (HBV) infection in renal transplant patients. Six patients were included in this study. They received 150 mg/day of lamivudine during a follow-up period of 24 months. The laboratory tests monitored were HBV DNA, HBsAg, HBeAg, ALT, gamma-GT, serum creatinine and blood cyclosporine levels. The HBV DNA became undetectable in four patients as early as in the third month of treatment. After six months, the viral load was also negative in the other two patients, and remained so until 18 months of follow-up. The medication was well tolerated with no major side effects. Lamivudine was safe and effective in blocking HBV replication in renal transplant patients without any apparent increase in the risk of graft failure for the 24-month period of study. |
publisher |
Associação Brasileira de Divulgação Científica |
publishDate |
2002 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000200008 |
work_keys_str_mv |
AT santosfrl lamivudinetherapyforhepatitisbinrenaltransplantation AT haiashiar lamivudinetherapyforhepatitisbinrenaltransplantation AT araujomrt lamivudinetherapyforhepatitisbinrenaltransplantation AT abensurh lamivudinetherapyforhepatitisbinrenaltransplantation AT romaojuniorje lamivudinetherapyforhepatitisbinrenaltransplantation AT noronhail lamivudinetherapyforhepatitisbinrenaltransplantation |
_version_ |
1756391014497517568 |